FFRct

FFRct v2.0 is a software device that provides a non-invasive method for the functional assessment of coronary artery disease by analyzing patient-specific CT data to simulate coronary blood flow and derive fractional flow reserve values. Its methodology involves creating a 3D model of the coronary arteries from static CT images and applying computational fluid dynamics principles to calculate FFRct, aiming to improve diagnostic accuracy for hemodynamically significant stenoses compared to anatomical assessment with cCTA alone.

FFRct v2.0 is a coronary physiologic simulation software designed for the clinical quantitative and qualitative analysis of coronary artery disease (CAD) in clinically stable symptomatic patients. It utilizes previously acquired Computed Tomography (CT) DICOM data to generate a 3D computer model of the coronary arteries. From this model, the software simulates pressure, velocity, and blood flow, mathematically deriving a quantity known as FFRct. This FFRct value is intended to support the functional evaluation of CAD, providing clinicians with insights into the hemodynamic significance of coronary artery obstructions to aid in their assessment and evaluation alongside other clinical information. Clinical validation for FFRct v2.0, utilizing data from the HeartFlowNXT study, demonstrated robust diagnostic performance. In per-vessel analysis against invasive Fractional Flow Reserve (FFR ≤ 0.80 as the reference standard for disease), FFRct achieved a sensitivity of 84.2% and a specificity of 84.9%. On a per-subject basis, when compared to site-read coronary CT angiography (cCTA using >50% stenosis criteria) with invasive FFR as the reference, FFRct showed superior diagnostic accuracy (80.0% for FFRct vs. 51.9% for cCTA) and notably higher specificity (76.4% for FFRct vs. 32.9% for cCTA). These findings suggest that FFRct offers an enhanced functional assessment over anatomical cCTA alone, potentially improving the identification of hemodynamically significant lesions non-invasively.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of FFRct v2.0 vary across different CT scanner manufacturers and imaging protocols beyond those included in the HeartFlowNXT validation dataset?; What is the quantitative impact of varying levels of CT image quality (e.g., noise, artifacts, calcification) on the accuracy and reliability of the FFRct calculations?; What is the learning curve for clinicians to effectively interpret FFRct results and integrate them into their decision-making process, particularly in complex anatomical scenarios?; How does FFRct performance compare in specific challenging patient subgroups, such as those with prior coronary artery bypass grafts, in-stent restenosis, or diffuse coronary artery disease?; Are there planned or ongoing studies to evaluate the long-term clinical outcomes and cost-effectiveness of incorporating FFRct analysis into standard diagnostic pathways for suspected coronary artery disease?